NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, JAPAN, CANADA, AUSTRALIA OR ANY OTHER JURISDICTION IN…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, JAPAN, CANADA, AUSTRALIA OR ANY OTHER JURISDICTION IN…
Continued focus on increased direct sales
"The second half of the year started off very well for Devyser. Sales remained strong during the quarter, and operations continued to develop in…
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, JAPAN, CANADA, AUSTRALIA OR ANY OTHER JURISDICTION IN…
Stockholm, September 30, 2021 – Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announced that Pia Gideon was elected as a new Board member at the…
Stockholm, February 2, 2021 - Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announced the completion of a private placement of 7,465 shares, corresponding…
Stockholm, January 19, 2021 - Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announced that it has been awarded funding through the Eurostars-2 program for…
Devyser, Swedish molecular diagnostics company, is pleased to announce that it has received certification for the successful completion of a Quality Management System audit under the…
Swedish genetic test developer Devyser's product for hereditary breast and ovarian cancer (HBOC) is now CE labelled and approved for diagnostic use in the EU. The kit is based on…
Swedish molecular diagnostics company Devyser, announced today at the 45th annual European Bone Marrow Transplantation (EBMT) meeting in Frankfurt, Germany, the release of a new NGS-based…
